{"id":226644,"date":"2026-09-02T10:26:18","date_gmt":"2026-09-02T04:56:18","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=226644"},"modified":"2026-09-02T10:26:19","modified_gmt":"2026-09-02T04:56:19","slug":"alembic-pharmaceuticals-share-price-buy-hold-or-sell","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/","title":{"rendered":"Alembic Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Alembic Pharmaceuticals share price Rs 838 (NSE), up 0.37% today. 52-week range Rs 635.80 to Rs 998. PE 24x versus sector 38x. Q1 FY27 revenue up 25.66% YoY to Rs 2,150 crore.<\/em><\/p>\n<div style=\"background: #F0F9FF; border-left: 4px solid #2E7D32; border-radius: 6px; padding: 14px 18px; margin: 18px 0;\">\n<p style=\"margin: 0; color: #1f4e79; font-size: 14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin: 8px 0 0;\">Alembic Pharmaceuticals share price is trading around Rs 838, roughly 16 percent below its 52-week high of Rs 998 and well above its 52-week low of Rs 635.80. The stock trades at 24 times earnings, a discount to the pharmaceutical sector average near 38 times, while Q1 FY27 revenue grew 25.66 percent year on year to Rs 2,150 crore and net profit rose about 12 percent to Rs 172 crore, aided by strong US generic launches. Investors comfortable with the company&#8217;s US branded business investment cycle may see the current valuation as reasonable, while those wanting clearer near-term margin expansion may prefer to wait.<\/p>\n<\/div>\n<p>Alembic Pharmaceuticals share price has pulled back from its 52-week high of Rs 998, and the Alembic Pharmaceuticals share price now trades near Rs 838 on the NSE, though it remains well above its 52-week low of Rs 635.80. That leaves investors weighing whether this generics-focused pharma company is a buy at current levels, a hold for existing shareholders, or a stock to trim given near-term margin pressure from US business investments.<\/p>\n<p>This Alembic Pharma stock analysis covers the latest Q1 FY27 results, valuation against the pharmaceutical sector, shareholding pattern and the technical setup, before laying out the Alembic Pharma buy or sell case using figures sourced from exchange filings and public disclosures.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=alembic_bhs\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#About_Alembic_Pharmaceuticals\" title=\"About Alembic Pharmaceuticals\">About Alembic Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Alembic_Pharmaceuticals_Share_Price_Today_Key_Levels\" title=\"Alembic Pharmaceuticals Share Price Today: Key Levels\">Alembic Pharmaceuticals Share Price Today: Key Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Alembic_Pharmaceuticals_Financial_Performance\" title=\"Alembic Pharmaceuticals Financial Performance\">Alembic Pharmaceuticals Financial Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Valuation_Check_Is_Alembic_Pharmaceuticals_Share_Price_Expensive\" title=\"Valuation Check: Is Alembic Pharmaceuticals Share Price Expensive?\">Valuation Check: Is Alembic Pharmaceuticals Share Price Expensive?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Technical_Signals_What_the_Chart_Shows\" title=\"Technical Signals: What the Chart Shows\">Technical Signals: What the Chart Shows<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Shareholding_Pattern\" title=\"Shareholding Pattern\">Shareholding Pattern<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Why_Investors_Are_Watching_Alembic_Pharmaceuticals\" title=\"Why Investors Are Watching Alembic Pharmaceuticals\">Why Investors Are Watching Alembic Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Risks_and_Factors_to_Watch\" title=\"Risks and Factors to Watch\">Risks and Factors to Watch<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Alembic_Pharmaceuticals_Share_Price_Target_What_the_Data_Suggests\" title=\"Alembic Pharmaceuticals Share Price Target: What the Data Suggests\">Alembic Pharmaceuticals Share Price Target: What the Data Suggests<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Alembic_Pharmaceuticals_Should_You_Buy_Hold_or_Sell_Right_Now\" title=\"Alembic Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?\">Alembic Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Q1_Is_Alembic_Pharmaceuticals_a_good_stock_to_buy_right_now\" title=\"Q1. Is Alembic Pharmaceuticals a good stock to buy right now?\">Q1. Is Alembic Pharmaceuticals a good stock to buy right now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Q2_What_is_the_Alembic_Pharmaceuticals_share_price_today\" title=\"Q2. What is the Alembic Pharmaceuticals share price today?\">Q2. What is the Alembic Pharmaceuticals share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Q3_What_is_the_Alembic_Pharmaceuticals_share_price_target\" title=\"Q3. What is the Alembic Pharmaceuticals share price target?\">Q3. What is the Alembic Pharmaceuticals share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Q4_Why_did_Alembic_Pharma_profit_decline_sequentially_in_Q1_FY27\" title=\"Q4. Why did Alembic Pharma profit decline sequentially in Q1 FY27?\">Q4. Why did Alembic Pharma profit decline sequentially in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Q5_What_is_Alembic_Pharmaceuticals_market_capitalisation_and_PE_ratio\" title=\"Q5. What is Alembic Pharmaceuticals&#8217; market capitalisation and PE ratio?\">Q5. What is Alembic Pharmaceuticals&#8217; market capitalisation and PE ratio?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-share-price-buy-hold-or-sell\/#Q6_What_is_the_shareholding_pattern_of_Alembic_Pharmaceuticals\" title=\"Q6. What is the shareholding pattern of Alembic Pharmaceuticals?\">Q6. What is the shareholding pattern of Alembic Pharmaceuticals?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"About_Alembic_Pharmaceuticals\"><\/span><strong>About Alembic Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Keep this backdrop in mind when reading the rest of this Alembic Pharmaceuticals share price review. That context matters when weighing Alembic Pharmaceuticals share price against peers. Before deciding on Alembic Pharmaceuticals share price, it helps to understand the underlying business. Alembic Pharmaceuticals Ltd. is a Vadodara-based, India-headquartered pharmaceutical company with a diversified business spanning India branded formulations, US generics, international formulations outside the US, and active pharmaceutical ingredients (API). The company has built a substantial US generics presence, backed by 245 total USFDA approvals as of recent disclosures.<\/p>\n<p>Alembic Pharma&#8217;s management has flagged that ongoing investments in its US branded specialty business are weighing on near-term margins, though the company expects this drag to reduce as sales in that specialty segment continue to ramp up over coming quarters, alongside continued exclusivity benefits on select products like Bosutinib.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alembic_Pharmaceuticals_Share_Price_Today_Key_Levels\"><\/span><strong>Alembic Pharmaceuticals Share Price Today: Key Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below summarises where Alembic Pharma share price stands right now against its recent trading range and market value.<\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/stocks\/aplltd\/alembic-pharmaceuticals-ltd-share-price-today\">Alembic Pharmaceuticals<\/a> CMP (NSE)<\/td>\n<td>Rs 838.00<\/td>\n<\/tr>\n<tr>\n<td>Alembic Pharmaceuticals CMP (BSE)<\/td>\n<td>Rs 837.55<\/td>\n<\/tr>\n<tr>\n<td>Day&#8217;s Change<\/td>\n<td>+0.37% (Rs +3.10)<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 998.00<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 635.80<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>Approximately Rs 16,430 crore<\/td>\n<\/tr>\n<tr>\n<td>NSE Volume (latest session)<\/td>\n<td>90,627 shares<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Alembic Pharma share price is trading in the middle of its 52-week range, reflecting a business balancing strong revenue growth against near-term margin investment in its US branded specialty segment.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Stock Data<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alembic_Pharmaceuticals_Financial_Performance\"><\/span><strong>Alembic Pharmaceuticals Financial Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Track this line item closely if you are following Alembic Pharmaceuticals share price closely. These results are the single biggest driver of Alembic Pharmaceuticals share price in the near term. The Alembic Pharmaceuticals share price trend is closely tied to how these numbers evolve each quarter. Alembic Pharmaceuticals reported Q1 FY27 net sales growth of 25.66 percent year on year to Rs 2,149.77 crore, driven substantially by strong US generic launches and continued exclusivity benefits, though consolidated net profit of Rs 173.07 crore represented a sequential decline of 14.62 percent from Q4 FY26 even as it improved 12.11 percent year on year.<\/p>\n<p>Management has raised its FY27 US growth outlook following the strong Q1 performance, citing Bosutinib exclusivity continuing until November as a near-term tailwind for Q2 US sales, while acknowledging that ongoing investments in the US branded specialty business continue to weigh on overall margins in the near term.<\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<th>Period<\/th>\n<th>Revenue<\/th>\n<th>Net Profit<\/th>\n<th>Comment<\/th>\n<\/tr>\n<tr>\n<td>Q1 FY27 (Jun 2026)<\/td>\n<td>Rs 2,149.77 crore<\/td>\n<td>Rs 173.07 crore<\/td>\n<td>+25.66% revenue, +12.11% profit YoY<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_Check_Is_Alembic_Pharmaceuticals_Share_Price_Expensive\"><\/span><strong>Valuation Check: Is Alembic Pharmaceuticals Share Price Expensive?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>It is one of the clearest signals available on Alembic Pharmaceuticals share price today. Investors comparing Alembic Pharmaceuticals share price with peers usually start here. Any view on Alembic Pharmaceuticals share price should start from these valuation multiples. Alembic Pharma share price currently reflects a price to earnings ratio of about 24 times trailing earnings, a discount to the broader pharmaceutical sector average of roughly 38 times. The price to book ratio stands near 2.9 times, with return on equity at 11.89 percent, a reasonable though not exceptional figure for a generics-focused pharma company.<\/p>\n<p>Debt to equity of 0.25 is modest, and the stock offers a dividend yield of 1.44 percent. Historically, pharmaceutical companies with strong US generics pipelines and rising branded specialty exposure have re-rated toward sector-average multiples once new segment investments begin showing improved returns, so the current discount is a useful benchmark to track against future margin trends.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Signals_What_the_Chart_Shows\"><\/span><strong>Technical Signals: What the Chart Shows<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Price action here often foreshadows the next move in Alembic Pharmaceuticals share price. Alembic Pharma share price is currently positioned about 16 percent below its 52-week high of Rs 998 and roughly 32 percent above its 52-week low of Rs 635.80, placing it in the middle of its annual trading range. A stock trading near the midpoint of its range, following a quarter of strong revenue growth but a sequential profit dip, often reflects the market weighing near-term margin investment against longer-term US business potential.<\/p>\n<p>Trading volumes remain moderate, so investors should track Alembic Pharma share price over several sessions, particularly around upcoming Q2 results where the Bosutinib exclusivity benefit is expected to be a factor, rather than reacting to any single day&#8217;s move at these technical levels.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Alembic Pharma&#8217;s live price and technical levels.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Shareholding_Pattern\"><\/span><strong>Shareholding Pattern<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This is a useful lens for reading Alembic Pharmaceuticals share price over time. Shifts here can influence Alembic Pharmaceuticals share price more than headline news on some sessions. Promoter shareholding in Alembic Pharmaceuticals stands at approximately 69.9 percent as of the latest available data, with foreign institutional investors holding around 4.2 percent, domestic institutions around 7.2 percent, and public shareholders holding roughly 10 percent of the equity.<\/p>\n<p>This high promoter concentration reflects the long-standing family ownership structure typical of many established Indian pharmaceutical companies.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Investors_Are_Watching_Alembic_Pharmaceuticals\"><\/span><strong>Why Investors Are Watching Alembic Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Strong US generics growth:<\/strong> Q1 FY27 revenue grew 25.66 percent year on year, driven by robust US generic launches and continued exclusivity benefits on select products.<\/li>\n<li><strong>Valuation discount to sector:<\/strong> A 24x PE against a 38x sector average leaves room for re-rating as the US branded specialty investment cycle matures.<\/li>\n<li><strong>Raised FY27 US growth outlook:<\/strong> Management has raised its FY27 US growth guidance following the strong Q1 print, citing continuing Bosutinib exclusivity into Q2.<\/li>\n<li><strong>Extensive USFDA approval base:<\/strong> 245 total USFDA approvals give Alembic Pharma a broad platform for continued US generic product launches.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Risks_and_Factors_to_Watch\"><\/span><strong>Risks and Factors to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Near-term margin pressure:<\/strong> Investments in the US branded specialty business are weighing on overall margins, with profit declining 14.62 percent sequentially in Q1 FY27 despite strong revenue growth.<\/li>\n<li><strong>Dependence on exclusivity windows:<\/strong> Part of the near-term US growth outlook is tied to time-limited exclusivity on products like Bosutinib, which will eventually face increased competition.<\/li>\n<li><strong>Sector-wide pricing pressure:<\/strong> Like all generics-focused pharma companies, Alembic Pharma faces periodic US pricing pressure and competitive intensity in its generics portfolio.<\/li>\n<li><strong>High promoter concentration:<\/strong> With promoters holding around 69.9 percent, the free float is relatively limited, which can affect stock liquidity.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Alembic_Pharmaceuticals_Share_Price_Target_What_the_Data_Suggests\"><\/span><strong>Alembic Pharmaceuticals Share Price Target: What the Data Suggests<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>That is a key gap in the public data on Alembic Pharmaceuticals share price today. Until then, Alembic Pharmaceuticals share price remains best tracked through live, verified data rather than a single fixed number. Alembic Pharma does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company with strong revenue momentum trading at a discount to its sector, while working through a margin investment cycle in its US branded specialty business.<\/p>\n<p>Historically, pharmaceutical companies have re-rated once new segment investments begin contributing positively to margins rather than diluting them. Investors who want live, updated target price research can check the Univest Screener, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alembic_Pharmaceuticals_Should_You_Buy_Hold_or_Sell_Right_Now\"><\/span><strong>Alembic Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This is the core question behind Alembic Pharmaceuticals share price right now. The Alembic Pharma buy or sell decision depends on how you weigh strong revenue growth against near-term margin pressure from the US business investment cycle.<\/p>\n<p><strong>The case for buying:<\/strong> Investors who believe in Alembic Pharma&#8217;s US generics growth trajectory and are comfortable with near-term margin investment may see the stock&#8217;s discount to sector PE, combined with raised FY27 US guidance, as an attractive entry point.<\/p>\n<p><strong>The case for holding:<\/strong> Existing shareholders who already track the company&#8217;s US branded specialty ramp-up may prefer to stay invested and watch for margin improvement as investments mature over coming quarters.<\/p>\n<p><strong>The case for trimming or waiting:<\/strong> Investors who prefer to see the US branded investment cycle actually turn margin-accretive, or who are cautious about the sequential profit decline in Q1 FY27, may prefer to wait for clearer evidence before adding fresh exposure.<\/p>\n<p>Historically, well-executed pharma growth investments have paid off over a multi-year horizon, but near-term margin dilution can persist longer than expected, so weigh this against your own investment horizon and consult a SEBI-registered investment adviser if unsure.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alembic Pharma share price reflects a pharmaceutical company delivering strong US-led revenue growth while investing in its branded specialty business, trading at a discount to the broader pharma sector on PE despite that near-term margin pressure. Whether that combination makes the stock a buy, a hold or a candidate to trim depends on your confidence in the US branded business investment paying off over time. This article is for informational purposes and not a personalised investment recommendation.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"Q1_Is_Alembic_Pharmaceuticals_a_good_stock_to_buy_right_now\"><\/span><strong>Q1. Is Alembic Pharmaceuticals a good stock to buy right now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharma delivered 25.66 percent revenue growth in Q1 FY27 and trades at a discount to the pharma sector on PE, which appeals to value-focused investors. However, near-term margins are being weighed down by US branded specialty investments, so growth in profit has lagged revenue growth recently.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q2_What_is_the_Alembic_Pharmaceuticals_share_price_today\"><\/span><strong>Q2. What is the Alembic Pharmaceuticals share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharmaceuticals share price is trading around Rs 838 on the NSE, up about 0.37 percent on the day. The stock&#8217;s 52-week high is Rs 998 and its 52-week low is Rs 635.80.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q3_What_is_the_Alembic_Pharmaceuticals_share_price_target\"><\/span><strong>Q3. What is the Alembic Pharmaceuticals share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharma does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser for a personalised view.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q4_Why_did_Alembic_Pharma_profit_decline_sequentially_in_Q1_FY27\"><\/span><strong>Q4. Why did Alembic Pharma profit decline sequentially in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharma&#8217;s Q1 FY27 net profit fell 14.62 percent sequentially from Q4 FY26, even as it rose 12.11 percent year on year, mainly due to ongoing investments in the company&#8217;s US branded specialty business weighing on margins.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q5_What_is_Alembic_Pharmaceuticals_market_capitalisation_and_PE_ratio\"><\/span><strong>Q5. What is Alembic Pharmaceuticals&#8217; market capitalisation and PE ratio?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharmaceuticals has a market capitalisation of approximately Rs 16,430 crore and trades at a price to earnings ratio of about 24 times, a discount to the pharmaceutical sector average PE of roughly 38 times.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q6_What_is_the_shareholding_pattern_of_Alembic_Pharmaceuticals\"><\/span><strong>Q6. What is the shareholding pattern of Alembic Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Promoter shareholding in Alembic Pharmaceuticals stands at approximately 69.9 percent, with foreign institutions holding around 4.2 percent, domestic institutions around 7.2 percent, and public shareholders holding roughly 10 percent.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alembic Pharmaceuticals share price trades at a discount to sector PE as US-led revenue grows 25.66% in Q1 FY27, even as margins face near-term pressure.<\/p>\n","protected":false},"author":35,"featured_media":226643,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[3802],"class_list":["post-226644","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["226643"],"_edit_lock":["1788324985:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["24"],"rank_math_seo_score":["60"],"rank_math_title":["Alembic Pharma Share Price: Buy, Hold or Sell"],"rank_math_description":["Alembic Pharmaceuticals share price today, Q1 FY27 results, valuation and shareholding pattern explained, with a balanced buy, hold or sell view."],"rank_math_focus_keyword":["Alembic Pharma Share Price"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["40809"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/alembic-pharmaceuticals-share-price-buy-hold-or-sell.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/226644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=226644"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/226644\/revisions"}],"predecessor-version":[{"id":226887,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/226644\/revisions\/226887"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/226643"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=226644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=226644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=226644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}